Is cystatin C the answer to detecting progression in CKD?

Journal of the American Society of Nephrology

Volumn 22, Issue 1, 2011, Pages 9-11

  De Jong, Paul E ^a   Gansevoort, Ron T ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CYSTATIN C;

ALBUMINURIA; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DISEASE COURSE; EDITORIAL; GLOMERULUS FILTRATION RATE; HEART FAILURE; MORTALITY; PRIORITY JOURNAL;

EID: 78651410599     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2010111189     Document Type: Editorial

References (16)

1. Peralta CA, Katz R, Sarnak MJ, Ix J, Fried LF, De Boer I, Palmas W, Siscovick D, Levey AS, Shlipak MG: Cystatin C identifies chronic kidney disease patients at higher risk for complications. J Am Soc Nephrol 22: 147-155, 2011
2. Matsushita K, Selvin E, Bash LD, Astor BC, Coresh J: Risk implications of the new CKD Epidemiology Collaboration (CKD-EPI) equation compared with the MDRD study equation for estimated GFR: The Atherosclerosis Risk in Communities (ARIC) study. Am J Kidney Dis 55: 648-659, 2010
3. White SL, Polkinghorne KR, Atkins RC, Chadban SJ: Comparison of the prevalence and mortality risk of CKD in Australia using the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study GFR estimating equations: The AusDiab (Australian Diabetes, Obesity and Lifestyle) study. Am J Kidney Dis 55: 660-670, 2010
4. O'Hare AM, Choi AI, Bachetti P, Garg AX, Kaufman JS, Walter LC, Mehta KM, Steinman MA, Allon M, McClellan WM, Landefeld CS: Age affects outcomes in chronic kidney disease. J Am Soc Nephrol 18: 2758-2765, 2007
5. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT: Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative meta-analysis. Lancet 375: 2073-2081, 2010
6. Chronic Kidney Disease Prognosis Consortium, Gansevoort RT, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J: Association of estimated glomerular filtration rate and albuminuria with kidney outcomes: A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int 2010, in press
7. Stevens LA, Coresh J, Schmid CH, Feldman HI, Froissart M, Kusek J, Rossert J, van Lente F, Bruce RD, Zhang Y, Greene T, Levey AS: Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 51: 395-406, 2008
8. Knight EL, Verhave JC, Spiegelman D, Hillege HL, de Zeeuw D, Curhan GC, de Jong PE: Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 65: 1416-1421, 2004 (Pubitemid 38406982)
9. Naour N, Fellahi S, Renucci JF, Poitou C, Rouault C, Basdevant A, Dutour A, Alessi MC, Bastard JP, Clément K, Guerre-Millo M: Potential contribution of adipose tissue to elevated serum cystatin C in human obesity. Obesity 17: 2121-2126, 2009
10. Young JA, Hwang SJ, Sarnak MJ, Hoffmann U, Massaro JM, Levy D, Benjamin EJ, Larson MG, Vasan RS, O'Donnell CJ, Fox CS: Association of visceral and subcutaneous adiposity with kidney function. Clin J Am Soc Nephrol 3: 1786-1791, 2008
11. Singh D, Whooley MA, Ix JH, Ali S, Shlipak MG: Association of cystatin C and estimated GFR with inflammatory biomarkers: The Heart and Soul Study. Nephrol Dial Transplant 22: 1087-1092, 2007 (Pubitemid 46523422)
12. Wiesli P, Schwegler B, Spinas GA, Schmid C: Serum cystatin C is sensitive to small changes in thyroid function. Clin Chim Acta 338: 87-90, 2003
13. Atthobari J, Asselbergs FW, Boersma C, de Vries R, Hillege HL, van Gilst WH, Gansevoort RT, de Jong PE, de Jong-van den Berg LT, Postma MJ: Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular end stage disease intervention trial. Clin Ther 28: 432-444, 2006
14. Boersma C, Gansevoort RT, Pechlivanoglou P, Visser ST, van Toly FF, de Jong-van den Berg LT, de Jong PE, Postma MJ: Screen-and-treat strategies for albuminuria to prevent cardiovascular and renal disease: Cost-effectiveness of nationwide and targeted interventions based on analysis of cohort data in the Netherlands. Clin Ther 32: 1103-1121, 2010
15. van der Velde M, de Jong PE, Gansevoort RT: Comparison of the yield of different screening approaches to detect chronic kidney disease. Nephrol Dial Transplant 25: 3222-3230, 2010
16. Rifkin DE, Katz R, Chonchol M, Fried LF, Cao J, de Boer IH, Siscovick DS, Shlipak MG, Sarnak MJ: Albuminuria, impaired kidney function and cardiovascular outcomes of mortality in the elderly. Nephrol Dial Transplant 25: 1560-1567, 2010